Treatment of Fibrous Dysplasia of Bone with Non-Autoimmune Hyperthyroidism in FD/MAS

In fibrous dysplasia of bone, thyroid involvement may occur as part of FD/MAS-related thyroid disease, resulting in non-autoimmune hyperthyroidism — a specific clinical scenario that requires a dedicated management approach.

Clinical scenario

Thyroid lesions consistent with FD/MAS, presenting with or without non-autoimmune hyperthyroidism. The hyperthyroid state in this context is not autoimmune in origin, distinguishing it from conditions such as Graves' disease and directing management accordingly.

Approach to management

Short-term management of the hyperthyroidism involves antithyroid medication. The selection of agent, duration, and what follows for longer-standing cases is addressed in full within the structured protocol.

The complete regimen — including decision criteria and subsequent steps — is available in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s13023-019-1102-9

Thyroid lesions consistent with FD/MAS with or without non-autoimmune hyperthyroidism.

In the short-term, carbimazole or methimazole are recommended for hyperthyroidism, whereas thyroidectomy or radio-ablation are recommended for long standing hyperthyroidism of more than 5 years.

View source ↗